

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (10 ml,
5 x 10 ml, 6 x 10 ml)**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Mepivacaine Richter 20 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Mepivacaine hydrochloride 20 mg/ml

3. PACKAGE SIZE

10 ml

5 x 10 ml

6 x 10 ml

4. TARGET SPECIES

Horses

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

For intra-articular and epidural use.

7. WITHDRAWAL PERIODS

Withdrawal period(s):

Meat and offal: 3 days

Milk: 72 hours

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

The veterinary medicinal product should not be administered by pregnant women.
Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VetViva Richter (logo)

14. MARKETING AUTHORISATION NUMBERS

Vm 57446/4009

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 10 ml clear glass vial type I with bromobutyl rubber stopper and alu-caps

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Mepivacaine Richter



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Mepivacaine hydrochloride 20 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

10 ml

Adverse effects on the foetus cannot be excluded. The veterinary medicinal product should not be administered by pregnant women.

Accidental self-injection may result in cardiorespiratory and/or CNS effects. Care should be taken to avoid accidental self-injection. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive.

Wash hands after use.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Mepivacaine crosses the placenta. There is no evidence that mepivacaine is associated with reproductive toxicity or teratogenic effects.

However, there is a potential for anaesthetics of the amide group such as mepivacaine to accumulate in the equine foetus resulting in neonatal depression and interfering with resuscitation efforts. Therefore, use in obstetric anaesthesia only according to the benefit/risk assessment of the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Mepivacaine should be used carefully in patients undergoing treatment with other local anaesthetics of the amide group since the toxic effects are additive.

Overdose:

Symptoms related to overdose correlate with symptoms occurring after inadvertent intravascular injection as described in section "Adverse reactions".

<Special restrictions for use and special conditions for use:>

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with any other veterinary medicinal products.

7. Adverse events

Horses:

Undetermined frequency (cannot be estimated from the available data):

Injection site swelling¹, Central nervous system disorder², Convulsion³, cardiac depression^{2,4}, respiratory depression^{2,4}.

¹ Transient.

² In case of inadvertent intra-vascular injection or excessive use local anaesthetics can cause systemic toxicity.

³ Administration of diazepam should be considered.

⁴ Administration of oxygen should be considered.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder

using the contact details at the end of this leaflet, or via your national reporting system at:

<https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicintheadverse.events@vmd.gov.uk>

8. Dosage for each species, routes and method of administration

Full aseptic precautions should be observed when injecting the veterinary medicinal product.

For intra-articular anaesthesia: 60 - 600mg of mepivacaine hydrochloride (3 to 30 ml of the medicinal product), dependent on joint size

For epidural use: 0.2 – 0.25 mg/kg (1.0 to 1.25 ml/100 kg), up to 10 ml/horse, depending on the depth and extent of anaesthesia required.

In all instances the dosage should be kept to the minimum required to produce the desired effect. The duration of action is about 1 hour. It is recommended that the skin should be shaved and thoroughly disinfected prior to the intra-articular or epidural administration.

This veterinary medicinal product does not contain an antimicrobial preservative. Use the vial on one occasion only. Discard any unused material.

9. Advice on correct administration

See section “Special warnings”.

10. Withdrawal periods

Meat and offal:	3 days
Milk:	72 hours

11. Special storage precautions

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after “Exp”. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: Use immediately

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 57446/4009

Pack sizes: 10 ml, 5 x 10 ml, 6 x 10 ml.
Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

VetViva Richter GmbH, Durisolstrasse 14, 4600 Wels, Austria
Tel: +43 (0)664 8455326
E-mail: adverse.events@vetviva.com

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall

Approved: 18 December 2025